![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Dymelor |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a602021 |
ATC code | |
Pharmacokinetic data | |
Protein binding | 90% |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.012.301 ![]() |
Chemical and physical data | |
Formula | C15H20N2O4S |
Molar mass | 324.40 g·mol−1 |
3D model (JSmol) | |
Melting point | 188 to 190 °C (370 to 374 °F) |
| |
| |
(verify) |
Acetohexamide (trade name Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.[1]
Acetohexamide binds to an ATP-sensitive K+ (KATP) channel on the cell membrane of pancreatic beta cells. This inhibits the outflux of potassium, which causes the membrane potential to become more positive. This depolarization in turn opens voltage-gated calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of insulin.[2]
Sulfonylureas, especially first-generation sulfonylureas such as Acetohexamide, can cause severe hypoglycemia and increase the risk of adverse cardiovascular events. [3][4]
| |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calcium |
| ||||||||||||||||||||||||
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
See also: Receptor/signaling modulators • Transient receptor potential channel modulators |
![]() | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |